We're also making progress on our liquid biopsy program
since our last update, including the recently announced collaboration with Memorial Sloan Kettering
Cancer Center, which is focused on furthering the basic understanding of the biology of circulating tumor DNA, or ctDNA, in different cancer
Cancer Center, which is focused on furthering the basic understanding
of the biology
of circulating tumor DNA, or ctDNA, in
different cancer cancer types.
As we have previously suggested,
since tumor angiogenesis is very complex and involves a number
of different cell
types, a multi-target approach for the anti-angiogenic treatment
of cancer could be expected to produce better results [18].